An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease On Nov. 6, Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine […]
